Patents by Inventor Michael Cory

Michael Cory has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of treating cancer
    Patent number: 12606521
    Abstract: Phenylsulfonamido compounds that inhibit genome-wide hypomethylation and can be used to treat cancer, including melanoma, prostate cancer, pancreatic cancer, breast cancer, colon cancer, lung cancer, ovarian cancer, and glioblastoma, are provided.
    Type: Grant
    Filed: August 30, 2021
    Date of Patent: April 21, 2026
    Assignee: Institute For Cancer Research
    Inventors: Alfonso Bellacosa, John Karanicolas, Timothy J. Yen, Michael Cory, Chris Parry, Rahul Prasad
  • METHODS OF TREATING CANCER
    Publication number: 20240190817
    Abstract: Phenylsulfonamido compounds that inhibit genome-wide hypomethylation and can be used to treat cancer, including melanoma, prostate cancer, pancreatic cancer, breast cancer, colon cancer, lung cancer, ovarian cancer, and glioblastoma, are provided.
    Type: Application
    Filed: August 30, 2021
    Publication date: June 13, 2024
    Inventors: Alfonso Bellacosa, John Karanicolas, Timothy J. Yen, Michael Cory, Chris Parry, Rahul Prasad
  • Nucleic acids encoding mutant human carboxypeptidase A enzymes
    Patent number: 6319702
    Abstract: The present invention relates to nucleic acid molecules encoding mutant human carboxypeptidase A enzymes, and encoding conjugates of targeting molecules and mutant human carboxypeptidase A enzymes. The invention further relates to vectors and cell lines containing such nucleic acid molecules.
    Type: Grant
    Filed: September 14, 1999
    Date of Patent: November 20, 2001
    Assignee: Glaxo Wellcome, Inc.
    Inventors: Gary Keith Smith, Todd Andrew Blumenkopf, Michael Cory
  • Cell-targeting molecule comprising a mutant human carboxypeptidase A
    Patent number: 6140100
    Abstract: Conjugates of a cell targetting molecule and a mutant human carboxypeptidase A enzyme are provided. Suitable targetting molecules include antibodies, hormones, ligands, cytokines, antigens, oligonucleotides and peptidomimetics. Enzymes comprising a mutant human carboxypeptidase A enzyme are also provided.
    Type: Grant
    Filed: May 9, 1996
    Date of Patent: October 31, 2000
    Assignee: Glaxo Wellcome Inc.
    Inventors: Gary Keith Smith, Todd Andrew Blumenkopf, Michael Cory
  • Paint denaturant
    Patent number: 5250191
    Abstract: This invention relates to a process for detackifying and dispersing paint solids for example obtained from paint overspray in enclosed areas such as paint spray booths.The process includes contacting an oil-in-water emulsion with an aqueous solution whereby the oil-in-water emulsion is destabilised. On subsequent contact of paint particles with the aqueous solution comprising the destabilised oil-in-water emulsion, the paint is adsorbed on to destabilised emulsion particles. The process provides an effective method of denaturing paint over-spray which is easily handleable and effective over a wide range of paint compositions.In one embodiment of the invention, the oil-in-water emulsion comprises a latex.
    Type: Grant
    Filed: June 24, 1992
    Date of Patent: October 5, 1993
    Assignee: Brent Chemicals International plc
    Inventors: Michael Cory, Ziegmund Zoltowski
  • N-substituted 2-[2-(5-nitro-2-furyl) vinyl]imidazoles
    Patent number: 3993643
    Abstract: N-substituted 2-[2-(5-nitro-2-furyl)vinyl]imidazoles having the structure ##STR1## wherein R represents mono- or dimethoxybenzyl, pyridylmethyl, N,N-dimethylaminobenzyl or phenoxypropyl. A preferred compound is 1-(4-methoxybenzyl)-2-[2-(5-nitro-2-furyl)vinyl]imidazole. The compounds have utility as antischistosomal chemotherapeutic agents.
    Type: Grant
    Filed: May 7, 1976
    Date of Patent: November 23, 1976
    Assignee: Stanford Research Institute
    Inventors: David W. Henry, Michael Cory